Clearmind reports MEAI intranasal study progress
- Clearmind reported successful formulation-feasibility results for intranasal delivery of MEAI.
- The study showed MEAI can be stably incorporated into a fully soluble intranasal solution.
- The company said the results support continued development of intranasal MEAI for alcohol use disorder.
Clearmind (NASDAQ:CMND) reported successful formulation-feasibility results for intranasal delivery of MEAI, its lead candidate initially aimed at treating alcohol use disorder.
The study tested whether MEAI could be delivered through the nose as an additional route of administration.
Clearmind said the study showed MEAI can be stably incorporated into an intranasal formulation as a fully soluble solution.
The company said the formulation results support continued development of this additional delivery route for MEAI, while the initial target remains alcohol use disorder.
Clearmind said the intranasal approach could become another route for MEAI development.
The company’s broader work is focused on developing psychedelic-derived therapeutics for alcohol use disorder and other conditions.
Recent company updates have centered on MEAI development, formulation work, intellectual property, and potential new administration routes for its treatment pipeline.
More from United States
Amazon Q3 revenue accelerates 12% to $201.9 billion as AWS growth accelerates
Intel Q3 revenue skyrockets 21% to $16.5B as data center sales surge
Merck raises FY profit outlook as Q3 revenue climbs 5% to $18.1B
Eli Lilly Q3 revenue surges 39% to $24.4 billion as guidance rises
Enterprise Products Q3 EBITDA jumps 16% to $2.8 billion
KBR Q3 revenue rises 5% to $2 billion as adjusted EBITDA grows 12%
